NYSE$ATR

AptarGroup Inc. · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Reported strong operational performance driven by Aptar’s Pharma and Beauty segments.

AptarGroup reported a positive start to 2023, with a 2% increase in reported sales and a 4% increase in core sales, driven by the Pharma and Beauty segments. Net income decreased by 12% to $55 million due to restructuring charges, while adjusted earnings per share increased by 2% to $0.95.

  • Reported sales grew 2% and core sales increased 4% driven by demand in Pharma and Beauty.
  • Aptar Pharma reported sales growth of 4% and core sales growth of 7%.
  • Aptar Beauty reported sales growth of 6% and core sales growth of 9%.
  • Adjusted earnings per share increased 2% to $0.95.

Headline financials

Total Revenue

$860M

Previous: $845M+1.8%
EPS (adj)

$0.95

Previous: $0.96-1.0%
Total Core Sales Growth

4.0%

Previous: 13.0%-69.2%
Pharma Core Sales Growth

7.0%

Previous: 13.0%-46.2%
Beauty Core Sales Growth

9.0%

Previous: 10.0%-10.0%
Closures Core Sales Growth

-8.0%

Previous: 18.0%-144.4%
Capital Expenditures

-$77.8M

Previous: -$73.1M-6.5%
Free Cash Flow

-$23.1M

Previous: -$10.6M-116.8%
Net Income

$54.8M

Previous: $62.4M-12.3%
Operating Income

$83.9M

Previous: $97.7M-14.1%
Gross Profit

$860M

Previous: $845M+1.8%
Cash & Equivalents

$127M

Previous: $356M-64.3%
Total Assets

$4.3B

Previous: $4.41B-2.4%
Stock-Based Comp

$15M

Previous: $13.4M+12.6%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$860M

Q1 2023+1.8%vs Q1 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

AptarGroup · $860M total across 3 segments · Q1 2023

  • Pharma
    $356M+4.0%
  • Beauty
    $326M-11.4%
  • Closures
    $178M+32.3%

Forward guidance

Aptar expects earnings per share for the second quarter of 2023, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.11 to $1.19.

Tailwinds

  • Strong momentum continuing
  • Proprietary pharma dispensing devices are expected to grow
  • Beauty solutions are expected to grow
  • Injectables division’s performance should improve as the division moves past its ERP system implementation.
  • Anticipate a gradual recovery in our Closures segment as customers, especially in North America, continue to work through their inventory.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro